Elina Berliba

434 total citations
16 papers, 338 citations indexed

About

Elina Berliba is a scholar working on Epidemiology, Genetics and Hepatology. According to data from OpenAlex, Elina Berliba has authored 16 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 8 papers in Genetics and 7 papers in Hepatology. Recurrent topics in Elina Berliba's work include Inflammatory Bowel Disease (8 papers), Hepatitis C virus research (7 papers) and Microscopic Colitis (7 papers). Elina Berliba is often cited by papers focused on Inflammatory Bowel Disease (8 papers), Hepatitis C virus research (7 papers) and Microscopic Colitis (7 papers). Elina Berliba collaborates with scholars based in Belgium, United States and Moldova. Elina Berliba's co-authors include Geert D’Haens, Bal Raj Bhandari, M. Durante, William J. Sandborn, Marc Ferrante, Jay Tuttle, Brian G. Feagan, Stuart Friedrich, Toshifumi Hibi∥ and Jochen Schmitz and has published in prestigious journals such as Gastroenterology, PLoS ONE and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Elina Berliba

16 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elina Berliba Belgium	9	209	187	117	57	48	16	338
Anthony Croft Australia	9	245 1.2×	203 1.1×	81 0.7×	32 0.6×	49 1.0×	17	324
Mireia Peñalva Spain	6	217 1.0×	170 0.9×	50 0.4×	13 0.2×	24 0.5×	16	300
Carmen Stefănescu France	10	410 2.0×	307 1.6×	73 0.6×	15 0.3×	49 1.0×	14	484
Antje Rhode Germany	6	148 0.7×	219 1.2×	251 2.1×	133 2.3×	71 1.5×	7	526
Safa Meshaal Egypt	12	78 0.4×	47 0.3×	178 1.5×	20 0.4×	48 1.0×	31	291
S Schreiber Germany	5	347 1.7×	293 1.6×	40 0.3×	23 0.4×	8 0.2×	22	406
Diana Seegers Netherlands	6	44 0.2×	84 0.4×	221 1.9×	21 0.4×	20 0.4×	8	355
Huifan Ji China	11	44 0.2×	127 0.7×	121 1.0×	96 1.7×	28 0.6×	21	330
Wafaa Badre Morocco	12	35 0.2×	97 0.5×	89 0.8×	63 1.1×	26 0.5×	40	295
C. Puapairoj Thailand	13	80 0.4×	79 0.4×	197 1.7×	40 0.7×	15 0.3×	27	397

Countries citing papers authored by Elina Berliba

Since Specialization

Citations

This map shows the geographic impact of Elina Berliba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elina Berliba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elina Berliba more than expected).

Fields of papers citing papers by Elina Berliba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elina Berliba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elina Berliba. The network helps show where Elina Berliba may publish in the future.

Co-authorship network of co-authors of Elina Berliba

This figure shows the co-authorship network connecting the top 25 collaborators of Elina Berliba. A scholar is included among the top collaborators of Elina Berliba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elina Berliba. Elina Berliba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Yuen, Man‐Fung, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.. (2022). Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B. Hepatology Communications. 6(12). 3457–3472. 17 indexed citations

Yuen, Man‐Fung, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.. (2022). Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Journal of Hepatology. 77. S876–S877. 10 indexed citations

Gane, Ed, Christian Schwabe, Elina Berliba, et al.. (2021). Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. Journal of Antimicrobial Chemotherapy. 77(4). 1102–1110. 11 indexed citations

Berliba, Elina, Stefan Bourgeois, Alina Jucov, et al.. (2020). A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects. Journal of Hepatology. 73. S357–S357. 8 indexed citations

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2020). Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 20(1). 105–115.e14. 48 indexed citations

D’Haens, Geert, Toshifumi Hibi∥, Marc Ferrante, et al.. (2020). P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment. Journal of Crohn s and Colitis. 14(Supplement_1). S559–S560. 1 indexed citations

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2019). Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 158(3). 537–549.e10. 179 indexed citations

Berliba, Elina, Frédéric Vanhoutte, Steven S. Good, et al.. (2019). Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis. Antimicrobial Agents and Chemotherapy. 63(12). 25 indexed citations

D’Haens, Geert, William J. Sandborn, Marc Ferrante, et al.. (2019). 1004 – Maintenence Treatment with Mirikizumab, a P19-Directed Il-23 Antibody: 52-Week Results in Patients with Moderately-Toseverely Active Ulcerative Colitis. Gastroenterology. 156(6). S–216. 1 indexed citations

10.

D’Haens, Geert, William J. Sandborn, Marc Ferrante, et al.. (2019). OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. Journal of Crohn s and Colitis. 13(Supplement_1). S026–S027. 5 indexed citations

11.

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2019). Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial. Gastroenterology. 156(6). S–1094. 2 indexed citations

12.

Sandborn, William J., Marc Ferrante, Raj Bhandari, et al.. (2019). P033 EFFICACY OF MIRIKIZUMAB ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY. Gastroenterology. 156(3). S23–S23. 1 indexed citations

13.

McClure, Matthew W., Elina Berliba, Tengiz Tsertsvadze, et al.. (2018). Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. PLoS ONE. 13(10). e0204974–e0204974. 8 indexed citations

14.

Sandborn, William J., Marc Ferrante, Bal Raj Bhandari, et al.. (2018). 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study. Gastroenterology. 154(6). S–1360. 18 indexed citations

15.

Zhou, Xuan, Elina Berliba, Frédéric Vanhoutte, et al.. (2018). AT-527, a pan-genotypic purine nucleotideprodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C. Journal of Hepatology. 68. S282–S282. 1 indexed citations

16.

Berliba, Elina, Tengiz Tsertsvadze, D. Guyader, et al.. (2016). AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients. Journal of Hepatology. 64(2). S404–S405. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact